Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies

By Carrera S.   Buque A.   Azkona E.   Aresti U.   Calvo B.   Sancho A.   Arruti M.   Nuño M.   Rubio I.   Lobera A.   Lopez C.   Vivanco G.  

Clinical and Translational Oncology, Vol. 16, Iss. 4, 2014-04 ,pp. : 339-350

Springer Publishing Company

Access to resources Recommend Favorite

Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

By Ayoola Ayodele   Barochia Amit   Belani Kiran   Belani Chandra P.  

Cancer Investigation, Vol. 30, Iss. 5, 2012-05 ,pp. : 433-446

Informa Healthcare

Access to resources Recommend Favorite

Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

By        

Molecular Medicine Reports, Vol. 10, Iss. 2, 2014-01 ,pp. : 931-938

Spandidos Publications

Access to resources Recommend Favorite

Mutational analysis of the insulinlike growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients

By              

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1073-1079

Science Publishers

Access to resources Recommend Favorite

Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

By Hayashi Hidetoshi   Nakagawa Kazuhiko  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 441-443

Future Medicine

Access to resources Recommend Favorite